Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SABSW

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SABSW
DateTimeSourceHeadlineSymbolCompany
21/05/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SABSWSAB Biotherapeutics Inc
21/05/202407:45GlobeNewswire Inc.SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
21/05/202406:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SABSWSAB Biotherapeutics Inc
06/05/202421:15GlobeNewswire Inc.SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
16/04/202421:15GlobeNewswire Inc.SAB Biotherapeutics Provides SAB-142 Trial UpdateNASDAQ:SABSWSAB Biotherapeutics Inc
08/04/202421:15GlobeNewswire Inc.SAB Biotherapeutics to Present at INNODIA Annual MeetingNASDAQ:SABSWSAB Biotherapeutics Inc
04/04/202422:15GlobeNewswire Inc.SAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
29/03/202422:15GlobeNewswire Inc.SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
26/03/202401:15GlobeNewswire Inc.SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentNASDAQ:SABSWSAB Biotherapeutics Inc
24/02/202400:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
09/02/202400:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
02/02/202423:30GlobeNewswire Inc.SAB Biotherapeutics Announces Executive Leadership ChangeNASDAQ:SABSWSAB Biotherapeutics Inc
24/01/202409:58GlobeNewswire Inc.SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:SABSWSAB Biotherapeutics Inc
03/01/202408:30GlobeNewswire Inc.SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitNASDAQ:SABSWSAB Biotherapeutics Inc
29/11/202323:30GlobeNewswire Inc.SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
20/11/202323:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202323:30GlobeNewswire Inc.SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202323:15GlobeNewswire Inc.SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
09/11/202323:30GlobeNewswire Inc.SAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
24/10/202322:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerNASDAQ:SABSWSAB Biotherapeutics Inc
19/10/202322:30GlobeNewswire Inc.SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
05/10/202322:30GlobeNewswire Inc.SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
02/10/202322:30GlobeNewswire Inc.SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
21/08/202322:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
21/06/202322:30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023NASDAQ:SABSWSAB Biotherapeutics Inc
30/05/202322:30GlobeNewswire Inc.SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionNASDAQ:SABSWSAB Biotherapeutics Inc
19/05/202322:30GlobeNewswire Inc.SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsNASDAQ:SABSWSAB Biotherapeutics Inc
16/05/202322:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
12/05/202322:30GlobeNewswire Inc.SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesNASDAQ:SABSWSAB Biotherapeutics Inc
09/05/202322:30GlobeNewswire Inc.SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ PlatformNASDAQ:SABSWSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABSW

Your Recent History

Delayed Upgrade Clock